Track topics on Twitter Track topics that are important to you
Dermira said today it has agreed to obtain exclusive, worldwide rights from Roche and its Genentech subsidiary to develop and commercialize lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for most indications, in a deal that could generate up to $1.4 billion for the pharma giant. Under the companies’ licensing agreement, Dermira will gain rights to lebrikizumab in atopic dermatitis and all other indications except interstitial lung diseases, such as idiopathic pulmonary fibrosis—indications to which Roche will retain rights. Roche tried and failed last year to advance lebrikizumab in asthma, acknowledging disappointing results from two Phase III trials in February 2016. The LAVOLTA II trial missed its primary endpoint by showing rates of asthma exacerbations in people with higher levels of serum periostin or blood eosinophils that were not statistically significant. However, the LAVOLTA I trial met its primary endpoint, showing a significant reduction in the ...NEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...